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ORIGINAL ARTICLE
Schizophrenia is a chronic psychotic illness with
significant social function impairment, and social
function outcome has been found to be associa-
ted with impaired cognitive performances.1 It is
strongly recommended that cognitive assessments
should be incorporated into individual-based spe-
cific pharmacologic and rehabilitation programs.2
On the other hand, cognitive deficits, such as
sustained attention, working memory, verbal
memory, and perceptual processes, are potential
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endophenotypic markers and useful probes for
the complex genetics of schizophrenia.3
The literature shows that cognitive deficits are
present in a substantial proportion of both recent
onset and chronic schizophrenia patients, and al-
most all cognitive domains are affected. These cog-
nitive deficits show a pattern of specific deficits
superimposed on a background of generalized
deficits.4 It has also been reported that the first
episode and chronic patients demonstrate compa-
rable levels of deficits.5–9 The clinical variables of
current age, age at onset, duration of illness and
level of initial neuropsychologic impairment do
not seem to systematically affect cognitive perform-
ance.5 Although certain clinical symptoms tended
to parallel the levels of neurocognitive deficits, the
improvements in cognitive performances could
not be accounted for by changes in symptoms.7,8
The cognitive deficits observed in schizophrenic
patients thus seemed stable and were largely inde-
pendent of extraneous factors, hence possible the
manifestations of a “static encephalopathy”.10
Nevertheless, as schizophrenia is markedly het-
erogeneous in its clinical manifestations, disease
courses and social functions, analysis of schizo-
phrenia as a group might have misleadingly ob-
scured the heterogeneity in the severity and profile
of neurocognitive performances.9,11,12 We wanted
to investigate whether or not such deficit patterns
are robust for subgroups of schizophrenia patients
across disease stages or levels of cognitive impair-
ment. Based on these data, we could then hypothe-
size on whether the cognitive deficits are the result
of a static encephalopathy or a degenerative pro-
cess. Furthermore, it is important to address how
cognitive performances are affected by individual
and disease-associated factors, as substantial vari-
ations in the severity of deficits have been found
across functional domains both within and be-
tween individual patients.4
Up to now, although relationships of selected
cognitive domains, including sustained attention
and executive function, have been reported for
schizophrenic patients in Taiwan,13 there have
been no systematic description of cognitive per-
formances in schizophrenia. The extent, profile
and severity of cognitive deficits and potential
rcontributing factors remain to be delineated. Ove
the years, we have followed up a substantial sam-
ple of community dwelling schizophrenic patients
after their index admissions with yearly neuro-
psychologic assessments, using a comprehensive
rneuropsychologic test battery covering the majo
cognitive domains. As the patients varied widely in
their demographic characteristics, disease course,
durations of illness, clinical symptoms and treat-
ment history, we were able to examine the effects
of demographic and clinical variables on initial
cognitive manifestations and subsequent change
patterns. This report will focus on the initial cross-
sectional cognitive performance, and the longi-
tudinal changes will be reported separately. The
main issues covered in this report thus include: (1)
the pattern and magnitude of deficits in global and
domain-specific performances of patients with
schizophrenia, hence, to examine whether there
are selective impairments among the functional
domains; (2) the associations of cognitive deficits
with a broad range of demographic and clinical
characteristics, especially disease chronicity and
severity, hence, to provide descriptive information
for factors contributing to the cognitive deficits.
Patients and Methods
Subjects
fSubjects in the current study were participants o
the Taiwan Psychopathology Study of Schizophre-
nia (TPSS). The TPSS was a prospective follow-up
study of schizophrenic patients spanning from
August 1993 to June 1998 (TPSS stage 1; previo yusl
reported as the Multi-dimensional Psychopatho-
logical Group Research Projects14), and which was
then extended from July 1998 to December 2001
(TPSS stage 2). The recruitment of subjects, psycho-
pathologic instruments/assessments employed
and follow-up methods/data schedules for TPSS
have been described in detail elsewhere.13,14
Briefly, during TPSS stage 1, consecutively admit-
ted schizophrenic patients were recruited from
the National Taiwan University Hospital and the
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university-affiliated Provincial Taoyuan Psychiatric
Center, and Taipei City Psychiatric Center to study
their historical characteristics, clinical manifesta-
tions, treatment response and post-hospitalization
course. Recruited subjects all met the diagnostic
criteria of the Diagnostic and Statistical Manual,
4th edition (DSM-IV) of schizophrenia and gave
their written informed consent. The diagnosis was
confirmed at discharge by three senior psychia-
trists independently, using all available caregiver
reports, previous medical records, observations
made during the index admission, and data gath-
ered by structural interview using the Chinese
version of the Diagnostic Interview for Genetic
Study (DIGS-CH).15 If there was any doubt, the
final diagnosis was reached through a consensus
meeting. Patients with a history of electroconvul-
sive therapy during the previous 6 months, mental
retardation, trauma-related change in conscious-
ness, psychoactive substance abuse, or physical ill-
ness that might cast doubt on the diagnosis were
excluded. Clinical assessments of clinical symp-
toms, treatment response, drug-related adverse 
effects, and psychosocial function were performed
at admission, on discharge and at 3, 6 and 12
months after discharge, and then yearly thereafter.
A total of 234 schizophrenic patients were en-
rolled during TPSS stage 1, who had been followed-
up for 2–4 years at the conclusion of TPSS stage 1.
At the start of TPSS stage 2, attempts were made
to re-contact all TPSS stage 1 participants; those
who renewed their consent were followed-up
yearly for a further 2.5 years. In addition to the
clinical assessments administered during TPSS
stage 1, a comprehensive neuropsychologic test
battery (described below) was further incorporated
into the yearly assessments. Of the original 234
TPSS subjects who were successfully traced and
who completed at least two neuropsychologic eval-
uations during the follow-up period, 122 (52.1%)
were subjects of this report. Comparisons between
the 122 cases included and the 112 cases who failed
to be approached or who completed less than two
neuropsychologic evaluations showed that there
was no significant difference in sex (χ2 = 0.07, p =
0.79), age (t = −1.26, p = 0.22), education (t = 0.33,
p = 0.74) and severity of initial clinical symptoms
(for all symptom factors, p > 0.05).
For comparison and to provide estimates of the
degree of deviation of schizophrenic patients’ neu-
ropsychologic performances, 94 healthy subjects
were recruited through advertisements and an-
nouncements within the hospitals. Although the
demographic characteristics could not be matched
individually, attempts were made to include con-
trols as closely matched in age, sex composition
and education levels as possible. The clinical and
neuropsychologic assessments of the control sub-
jects followed the same protocol as those for the
schizophrenic subjects. Evaluation using the DIGS-
CH interview was done to rule out neuropsychi-
atric illness, DSM-IV axis I disorders and axis II
schizophrenia-related personality disorders, men-
tal retardation, and alcohol/psychoactive substance
yuse within the past 1 year. The groups had nearl
equal gender distribution (48.9% males vs. 50%
males for comparison subjects vs. cschizophreni
cpatients, respectively). Compared to schizophreni
patients, comparison subjects were younger (mean
age ± standard deviation [SD], 28.61 ± 10.98 years
vs. 32.89 ± 7.14 years for comparison subjects vs.
schizophrenic patients respectively, p < 0.05) and
better educated (mean years of education, 13.52 ±
2.96 vs. 11.17 ± 2.82 for comparison subjects vs.
schizophrenic patients, respectively, p < 0.05). As
the differences in basic characteristics might have
confounded the estimation, we made statistical ad-
justments to account for the possible effects of age,
sex and education in standardizing patients’ neu-
rocognitive performance scores (described below).
Clinical assessments
Baseline information regarding age at onset of psy-
ychiatric symptoms, duration of illness and histor
of previous medication and hospitalization were
fcollected systematically. The Chinese version o
the Positive and Negative Syndrome Schedules
(PANSS),16 having sufficient interrater reliability,17
was used by trained senior research psychiatrists to
assess the clinical psychopathology at baseline and
tat follow-ups. Antipsychotic-induced movemen
disorders were assessed by the Extrapyramidal
Syndrome Rating Scale,18 which provided global
severity measures for tardive dyskinesia (ESRS–TD)
and Parkinsonism (ESRS–EPS) on a 0–7-point
Likert scale.
Considering that the current sample consisted
mainly of community living outpatients with mild
clinical symptoms, and most of the general psy-
chopathology subscale items of PANSS showed
rare occurrences and little variation in ratings, we
used seven positive subscale items and seven neg-
ative subscale items for symptomatologic analy-
ses. Our previous factor-analytic study showed that
the 14 PANSS positive and negative subscale items
regrouped into four symptom dimensions, i.e.
the negative (blunted affect, emotional withdrawal,
poor rapport, passive apathetic social withdrawal),
disorganization (conceptual disorganization, dif-
ficulty in abstract thinking, stereotyped thinking),
delusion/hallucination (delusions, hallucinatory
behavior, suspiciousness/persecution), and ex-
citement (excitement, hostility) factors. These
symptom dimensions were reported to be more
related to cognitive performance than the ori-
ginal PANSS subscales.13 We selected these 14
positive and negative subscale items to generate
the four mean factor scores for analyses in this
study.
Neuropsychologic tests and construction of
neurocognitive functional domain
The neuropsychologic test battery consisted of
the Wechsler Adult Intelligence Scale–revised
(WAIS–R), Wechsler Memory Scale–revised
(WMS–R), Wisconsin Card Sorting Test (WCST)
computerized version, Continuous Performance
Test (CPT) undegraded AX version, and Trail-
making test parts A and B (Trail-A, B). The com-
plete neuropsychologic evaluation took about 2.5
hours and was completed in the same day. As the
tests were of composite nature and probably mea-
sured overlapping neuropsychologic processes, in-
dividual items of the tests were re-categorized into
constructs of cognitive functional domains that
hypothetically reflected basic cognitive proc-
esses.11 According to Kremen et al, the cognitive
domains and their components included the 
following: (1) verbal ability (VA) = information,
similarity, comprehension (WAIS–R); (2) visual/
spatial ability (VS) = block design, picture ar-
rangement (WAIS–R); (3) abstraction/execution
(ABEX) = category achieved, perseverative response
(WCST), Trail-B; (4) verbal memory (VEM) = ver-
bal paired association, immediate and delayed;
(5) visual memory (VIM) = visual reproduction,
immediate and delayed (WMS–R); (6) perceptual/
motor (PEMO) = Trail-A, digit–symbol (WAIS–R);
(7) mental control (MC) = arithmetic, digit span
backward (WAIS–R); (8) attention (ATTN) = sensi-
tivity index d’ (CPT), digit span forward (WAIS–R).
To adjust for the effects of age, sex and educa-
tion on cognitive performance, the predictive scores
of individual cognitive test items of a subject were
calculated by using the regression coefficients
obtained from the regression of the cognitive
 scores on age, sex and education among the
94 comparison subjects. The difference between
the raw score and the predictive score was then
standardized by the root mean error of the re-
gression and was defined as the adjusted z score
of the individual test item. The comparison
group’s mean standardized z scores of the cogni-
tive domains were adjusted to a mean of 0 and SD
of 1. The standardized z scores of the schizo-
phrenic patients thus provided the extent of the de-
viation from the comparison group and the
tdirection of the z scores was adjusted so tha
higher scores indicated better performances.
From individual item z scores, cognitive domain
z scores could be generated by the summed aver-
age of the individual z scores of component items
within each domain. In turn, an overall neuropsy-
chologic performance index (NPI) was calculated
for each subject by the summed average of the in-
gdividual domain z scores. To examine the meanin
of clinical heterogeneity in cognitive performance,
gstudy subjects were further classified accordin
to the NPI into three severity subgroups: (1) those
within normal limits (WNL), NPI > −1 (n = 32,
24.2%); (2) those moderately impaired (MI), NPI
between −1 and −2.5 (n = 61, 46.2%); (3) those
severely impaired (SI), NPI < −2.5 (n = 39,
29.5%).
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Data analysis
Variables significantly associated with cognitive
performances were examined by comparisons
between subgroups defined according to specific
variables (sex, illness duration, type of antipsy-
chotics used, NPI). The correlations among demo-
graphic, clinical variables and cognitive domain
scores were also examined. The χ2 test was used
for categorical variables and the independent t test
or univariate analysis of variances (ANOVA) with
Scheffe’s post hoc analysis for continuous variables
Correlations among demographic, clinical history,
psychopathologic variables and cognitive impair-
ments were examined by Pearson’s correlational
analysis. For variables with non-normal distribu-
tions, root square transformation was undertaken
before the correlational analyses. Further multiple
regression analyses were used to explore the effects
of the demographic and clinical variables on the
cognitive variables. NPI and individual cognitive
domain mean z scores were regressed on a set 
of variables that were considered possibly con-
tributing to the cognitive performances, includ-
ing selective demographic variables (current age,
sex, education), clinical historical variables (age
at onset, duration of illness), concurrent neuro-
logic status (presence of tardive dyskinesia and
the severity of EPS) and the scores of the four
symptomatologic dimensions. Statistical analyses
were performed using SPSS version 10.0 (SPSS
Inc., Chicago, IL, USA).
Results
Table 1 shows the descriptive data of clinical his-
torical variables, symptomatologic dimensions,
medications, extrapyramidal side effects and per-
formances in cognitive domains of the patients.
Since the current study was an extension from a
previous longitudinal follow-up study, no sub-
ject was experiencing his/her first episode, and du-
ration of illness spanned a wide range (2–30 years)
with a mean ± SD of 10.09 ± 5.86 years. They were
mildly symptomatic as indicated by the low mean
PANSS factor scores. All patients were receiving
neuroleptics with a mean ± SD dose of 821.00 ±
526.92 mg chlorpromazine equivalents, and
27.0% of subjects were receiving atypical antipsy-
chotics (including 13% using clozapine). Patients
had poor WAIS–R verbal IQ (mean ± SD = 87.22 ±
16.04, compared with the 111.88 ± 13.26 of the
comparison subjects, p < 0.05) and global NPI
(mean NPI = −1.93, one sample t test, p < 0.05).
When classified by their NPIs, 24.2% (n = f32) o
subjects could be considered as performing within
the normal range (WNL group); 46.2% (n = 61)
were moderately impaired (MI group); and 29.2%
(n = 39) were severely impaired (SI group). Patients
were substantially impaired across all individual
domains (Table 1), with deficits (in z score units,
reflecting the number of standard deviations
gbelow the mean of comparison subjects) rangin
from −1.08 (visual/spatial ability) to −2.49 (verbal
ymemory). Verbal ability and visual/spatial abilit
were relatively preserved with domain z scores
around −1. In contrast, verbal memory, visual
memory, abstraction/execution, and attention
showed more severe impairments with deviations
around 2.5 SD. Male and female schizophrenic pa-
tients did not reveal significant difference in demo-
fgraphic and clinical characteristics and severity o
clinical symptoms and extrapyramidal side effects
(Table 1). Female patients outperformed male pa-
tients in verbal ability, visual/spatial ability and
verbal memory, with verbal memory showing the
greatest gender difference. No significant differ-
ence was found between patients using traditional
antipsychotics and those using second generation
antipsychotics (comparisons across the eight neu-
ropsychologic domains were not significant, all
ps > 0.05).
tFigure 1 reveals the performances in the eigh
tcognitive domains of patient groups with differen
durations of illness. Patients were subgrouped into
those with illness duration < t5 years, i.e. the shor
duration group (SG, n = 30); those with between
5 and 10 years of illness duration, i.e. the medium
duration group (MG, n = r48); and those longe
g than 10 years of illness duration, i.e. the lon
duration group (LG, n = 44). There was a general
 pattern of deterioration in all eight cognitive
fNeuropsychologic de icits in chronic schizophrenia patients
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groups of patients with short duration (< 5 years),
medium duration (5–10 years) and long duration
(> 10 years) of illness. VA = verbal ability; 
VS = visual-spatial ability; ABEX = abstraction/
execution; VEM = verbal memory; VIM = visual
memory; PEMO = perceptual/motor ability; 
MC = mental control; ATTEN = attention.
Table 1. Descriptive data of clinical historical variables, symptomatologic dimensions, extrapyramidal
symptoms and cognitive performances in schizophrenic patients*
Male (n = 61) Female (n = 61) Total (n = 122)
Clinical history variables
Current age (yr) 32.69 ± 6.69 33.08 ± 7.61 32.89 ± 7.14
Education (yr) 10.93 ± 2.61 11.41 ± 3.02 11.17 ± 2.82
Age at onset (yr) 21.92 ± 6.01 23.95 ± 6.69 22.94 ± 6.42
Duration of illness (yr) 10.79 ± 6.58 9.39 ± 5.00 10.09 ± 5.86
Symptomatologic dimensions
Negative symptoms 2.46 ± 1.14 2.46 ± 1.27 2.46 ± 1.20
Delusion-hallucination symptoms 2.52 ± 1.24 2.34 ± 1.21 2.45 ± 1.22
Cognitive symptoms 2.85 ± 1.20 2.69 ± 1.53 2.81 ± 1.37
Excitement symptoms 1.44 ± 0.71 1.50 ± 0.80 1.50 ± 0.78
Medication
Neuroleptics (mg/d) 883.33 ± 598.75 760.12 ± 444.57 821.00 ± 526.92
Anticholinergics (mg/d) 10.31 ± 5.17 10.89 ± 3.82 10.67 ± 2.34
Extrapyramidal system side effects
ESRS–tardive dyskinesia 0.34 ± 0.87 0.37 ± 6.80 0.35 ± 0.83
ESRS–Parkinsonism 1.31 ± 1.10 1.38 ± 1.22 1.34 ± 1.16
Cognitive performances
NPI −2.11 ± 1.08 −1.78 ± 1.17 −1.93 ± 1.13
Verbal ability† −1.40 ± 0.99 −0.93 ± 1.00 −1.16 ± 1.01
Visual-spatial ability† −1.35 ± 0.91 −0.75 ± 1.05 −1.08 ± 1.01
Abstraction/execution −2.38 ± 1.11 −2.27 ± 1.07 −2.32 ± 1.12
Verbal memory† −3.04 ± 2.73 −2.04 ± 2.63 −2.49 ± 2.71
Visual memory −2.53 ± 2.30 −2.33 ± 2.16 −2.41 ± 2.19
Perceptual/motor −2.19 ± 1.70 −1.74 ± 2.08 −1.95 ± 1.89
Mental control −1.85 ± 0.81 −1.64 ± 0.79 −1.72 ± 0.81
Attention −2.21 ± 1.69 −2.54 ± 2.17 −2.38 ± 2.00
*Data presented as mean ± standard deviation; †significant difference between male and female (p = 0.05). ESRS = Extrapyramidal
Syndrome Rating Scale; NPI = overall neuropsychologic performance index.
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domains in the disease course in that patients with
longer duration of illness tended to have poorer
performances in the majority of cognitive domains
(Figure 1). Among the domains, verbal memory, vi-
sual memory and attention showed overt progres-
sive deteriorations with increased chronicity, with z
scores of −1.72 to −3.34, −2.34 to −3.02, and −1.56
to −2.96 respectively. The other two domains that
showed a mild degree of decline were perceptual/
motor and mental control. The corresponding 
z score changes were z values of −1.30 to −2.32,
and −1.42 to −1.96, respectively. Although the
overall pattern of relative deficits in abstraction/
execution, visual memory, verbal memory and at-
tention were largely preserved across subgroups,
it was notable that verbal ability, visual/spatial
ability and abstraction/execution were almost
identical for the MG and SG subgroups, indicat-
ing no further worsening in subjects in the later
disease stages. The results suggest that although
abstraction/execution was affected in patients in
the early phase of the disease, it remains stationary
and does not further deteriorate as the disease pro-
gresses to the later stages. In contrast, verbal mem-
ory, visual memory and attention performances
declined with the passage of time, probably in the
first 5 years within disease onset.
Figure 2 shows the performance in the eight
cognitive domains of patient groups with different
degrees of impairment in overall NPI. Across sub-
groups with different severities of cognitive deficits,
the differences in each cognitive domain were, as
expected, significant among the three subgroups
(ANOVA with Scheffe’s post hoc comparisons, all
ps < 0.01). However, it was notable that differences
among the subgroups in magnitudes of deficits in
verbal ability, visual/spatial ability and abstraction/
execution were relatively small, while large rela-
tive deficits in verbal memory, visual memory and
attention were found. The deficits in these three
domains were most profound in the SI group
(Figure 2), which gave rise to the overall relative
deficit pattern of the profile of the total sample.
WNL patients and SI patients were further com-
ypared for possible differences in clinical histor
variables, treatment-related side effects and clinical
symptom profiles. The WNL group was signifi-
cantly better educated (t = 4.46, p < 0.001), with
older age at disease onset (t = 2.20, p = 0.03),
shorter duration of illness (t = −2.13, p = 0.04), less
severity of EPS (t = −2.34, p = 0.02), lower antipsy-
chotic dosage (t = −2.72, p = r0.009), and with fewe
negative and disorganized symptoms (t = −2.78,
p = 0.007; t = −5.10, p < 0.001, respectively).
Table 2 reveals the correlations among clinical
historical variables, clinical symptoms and deficits
in individual cognitive domains. The data showed
that there was a general pattern that poorer per-
formances were associated with less education,
longer duration of illness, severer clinical negative,
disorganization symptoms and EPS. It was nota-
 ble that current age, age at onset, positive and
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excitement symptoms were not associated with
any cognitive performance.
Table 3 shows the predictive variables of cogni-
tive deficits using multivariate regression analysis.
The predictive variables included demographic
characteristics (age, sex, education), duration of
illness, motor side effects (severity of EPS and
tardive dyskinesia) and the four clinical symptom
dimensions. The analytical model was significant
for all cognitive domains (R2 = 0.22−0.42) except
abstraction/execution (R2 = 0.16, p = 0.08). Many
of the variables with significant correlations in uni-
variate analyses were not significant on multivari-
ate analysis, indicating complex intercorrelations
among the variables. Disorganization symptoms
and education were the two most robust contri-
buting factors to cognitive domain performances
in terms of the number of domains involved (five
and four domains respectively) and the relatively
large regression coefficients. Duration of illness,
gender and severity of EPS also had scattered asso-
ciations with verbal ability, visual/spatial ability,
perceptual/motor and attention.
Discussion
This study described in detail the profiles of cog-
nitive deficits in 122 community living stable
schizophrenic patients. The results showed that
schizophrenic patients as a group had significant
impairments in neuropsychologic function with
a mean global deficit of 1.93 SDs relative to the
xcomparison subjects, after adjusting for age, se
fand education (Table 1). The mean deficits o
around 2 SDs in the current schizophrenic sample
are comparable to those reported in chronic schiz-
ophrenic patients,19 but larger in magnitude than
the 0.5–1.5 SDs reported for patients exp geriencin
their first episode.20 We thus emphasize that there
gmight be cognitive function deteriorations alon
the clinical course in schizophrenic patients, which
is substantiated by the data shown in Figure 1,
where a progressive pattern of cognitive function
impairment was clearly shown, especially in verbal
memory, visual memory, perceptual/motor, men-
tal control and attention. A relative deficit pattern
was also found in that more severe impairments
could be observed in verbal memory, visual/spatial
memory, abstraction/execution and attention func-
tions (mean z scores around −2.5) than in verbal
ability and visual/spatial ability (mean z scores
around −1).
The generalized deficits with disproportionate
impairments in attention, frontal-based executive
functions, and temporal-based memory found in
the current study replicate those reported in the
literature20–23 and this also supports that cognitive
impairments in schizophrenia might be character-
ized by selective involvement of frontotemporal
functions superimposed on a generalized disabil-
ity.4,20,21 The functional deficits were also associated
with changes in prefrontal and temporal structure
and volume in schizophrenic patients.23–25
Table 2. Correlations among demographic, clinical variables and z scores of performances in the eight cognitive domains
Verbal Visual-spatial Abstraction/ Verbal Visual Perceptual/ Mental 
Attention
ability ability execution memory memory motor control
Age −0.06 −0.004 −0.18 −0.14 −0.17 0.07 −0.05 0.12
Education 0.51* 0.07 −0.21† 0.43* 0.37* 0.22† 0.29* 0.40*
Duration of illness −0.12 −0.18† −0.24† −0.25* −0.20† −0.11 −0.13 −0.24*
Age at onset 0.09 0.24 −0.01 0.10 0.02 0.26 0.14 0.12
EPS severity −0.22† −0.21† −0.11 −0.10 −0.23† −0.23† −0.31* −0.31*
Negative −0.20† −0.15 −0.13 −0.20† −0.22† −0.13 −0.18† −0.28*
Cognitive −0.42* −0.36* −0.15 −0.31* −0.28* −0.28* −0.29* −0.39*
Positive −0.12 −0.14 −0.08 −0.07 −0.11 −0.15 −0.17 −0.18†
Excitement −0.01 −0.09 0.02 0.12 −0.03 −0.05 −0.13 −0.17
*p < 0.005; †p < 0.05. EPS severity = severity of extrapyramidal side effects from antipsychotic medications.
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Despite the evidence, there remains concern
that as the difficulty and complexity levels of the
tasks for individual cognitive domains were often
unmatched, the relative deficit pattern might have
simply reflected the difficulty levels rather than
genuine domain-specific impairments. Moreover,
a generalized deficit or a slowing in general pro-
cessing speed, rather than possible domain-specific
or task-specific deficits could have accounted for
the uneven performance pattern,26 since tasks with
selective attention/inhibition components and
those with a lexicon component were demon-
strated to be affected by the general processing
speed to a greater extent than those without in
schizophrenic patients.27,28 Indeed, negative symp-
toms and severity of extrapyramidal symptoms,
both clinical indicators for possible psychomotor
slowing, was associated with poorer performances
in those neurocognitive domains that were time-
bound and speed-dependent.
There are reasons to believe that the pattern of
differential deficits revealed by the current study
is not likely to be an artifact, as schizophrenic
and comparison subjects were equally exposed to
the task-difficulty effects which were controlled for
by the standardization of the cognitive data. The
comparisons of the z scores within schizophrenia
thus reflected the degree of relative domain-specific
differences after weighting against comparison
subjects rather than direct comparisons between
the domain performances within schizophrenia
subjects. In addition, neurocognitive ability was
considered as a composite construct of complex
cognitive processes, hence not likely to be ex-
plained by a general ability.29 Besides, the parsing
of neurocognitive function into distinct independ-
ent dimensions has been verified psychometrically
by previous factor or cluster analytic studies30 and
external validity was provided through their differ-
ential associations with historical variables and
clinical characteristics, especially the negative and
disorganization symptoms.29,31,32 More specifi-
cally from the current study, the cognitive domains
did show differential patterns of associations with
other noncognitive factors, supporting their rela-
tive independence.
tAnalysis of schizophrenia as a group migh
have misleadingly obscured the heterogeneity in
severity and profile of cognitive performances.11,12
yIndeed, schizophrenic subjects in the current stud
varied greatly in global severity of cognitive impair-
ments. Around 24.2% (n = 32) could be described
as performing without over impairment, 46.2%
(n = 61) as moderately impaired, and 29.2%
(n= 39) as remarkably impaired. The relative
deficit pattern of the entire group was less conspic-
uous among subgroups with less global impair-
tments and became apparent in those with the mos
rsevere global impairments due to the very poo
yperformances in verbal memory, visual memor
and attention. Subgroups defined by subjects’
flength of illness also revealed a similar pattern o
selective deficits. In the group with remarkable
impairment, the association of severe cognitive
impairments with lower educational achievement,
earlier age at onset, longer duration of illness,
more severe EPS, negative and disorganized symp-
toms, provided evidence for a separate subtype
within schizophrenia, e.g. the deficit type of schizo-
phrenia.33 tAnother intriguing finding was tha
these subgroups also differed in their deficit pro-
files. For those with least impairments, selective
impairment was most apparent for the abstraction/
 execution function, while for those with more
severe global deficits, the deficits in abstraction/
execution remained at about the same level as
those less severely impaired, and the worst perfor-
mances were found in verbal memory, mental con-
trol and attention. Ceiling effects in abstraction/
execution might have accounted for the findings.
In multivariate analyses, sex, education, dura-
tion of illness, disorganization symptoms and
severity of extrapyramidal symptoms were found
to contribute to individual domain performances
except for the domain of abstraction/execution,
independently. The pattern of relative abstraction/
execution, verbal memory/visual memory and at-
tention impairments was largely preserved for all
groups with different disease chronicity. Moreover,
the poorer performances in verbal memory, visual
memory and attention manifested by patients with
longer duration of illness suggested that decline
fNeuropsychologic de icits in chronic schizophrenia patients
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in performances in these domains might have
occurred over the passage of time. The possible
decline might not be simply age-related, since
current age and age at onset were not associated
with performance. The duration effects remained
robust for visual/spatial ability, verbal memory,
perceptual/motor, mental control and attention
after potential confounding factors were con-
trolled for in multiple regression analysis. The find-
ings were in contrast to results from first episode
patients that performances in most neurocognitive
domains remained stable or even improved.22,34
Considering that first episode subjects were mainly
younger aged with follow-up periods limited to
the immediate post-psychotic years, the evaluation
might have missed the critical period of cognitive
decline.35 The current finding of possible neuro-
cognitive declines was nonetheless limited by its
cross-sectional nature; further longitudinal studies
of patient samples stratified according to disease
chronicity and followed-up for sufficient periods
of time are required to solve this issue. Moreover,
should there be true decline, it should not be
taken as direct evidence of an ongoing neurode-
generative process, since natural age-related decline
in cognitive functions, cumulated treatment-related
side effects and environmental factors might com-
plicate the picture.36
Disorganization symptoms were the only clini-
cal symptoms showing consistent associations
with cognitive domain deficits in the current study.
Despite the attempts to explain clinical symptoms
in terms of cognitive dysfunction, they neverthe-
less exhibited complex relationships and the find-
ings were inconsistent. Variability in the nature of
cognitive domains under investigation, clinical
characteristics of the subjects, symptom definition
and classifications might have contributed to the
inconsistent findings.37,38 Studies in first episode
cases did not reveal consistent associations with
clinical symptoms even with large sample size up
to 301 subjects,9,34 but during subsequent follow-
up, associations with negative symptoms were
observed,7,39 indicating that clinical symptoms
in the early stage might be poorly representative
of cognitive deficits, while persistent symptoms
manifested in stable clinical states are related
to underlying cognitive dysfunction. This is sup-
rported by findings in stable patients with longe
yduration of illness that correlations with severit
of negative and disorganized symptoms were more
consistently reported.37,40,41 Nevertheless, the cor-
relations were modest at best, and clinical symp-
toms contributed to only 10–15% of the variance
in cognitive performances, and the longitudinal
development of cognitive dysfunction did not par-
gallel the change in clinical symptoms, suggestin
that psychopathology and cognitive deficits in
schizophrenia only partially overlap and might be
caused by distinct pathophysiologic processes.42
In the current study, negative symptoms were
yassociated with cognitive measures in primar
analysis but not in multivariate analysis. It is plau-
sible that the negative symptoms were defined
relatively narrowly, focusing on aspects of dimin-
ished affective expression, diminution in interper-
sonal contacts and social interests, while those
more directly reflective of cognitive dysfunction,
such as positive formal thought disorder, language
performances and abstract thinking ability, were
categorized as disorganization symptoms. In this
regard, the results concurred with previous reports
that syndromes of alogia, attentional impairment,
and positive formal thought disorder that reflected
primarily a disorganization of thought are more
closely associated with cognitive performances
than syndromes of affective flattening, avolition/
apathy, and anhedonia.43 Another possibility is
that it was often difficult to distinguish between
primary negative symptoms and extrapyramidal
symptoms. This appeared to be the case in the cur-
rent study, since negative symptoms and extrapyra-
midal symptoms were moderately correlated
(r = 0.47, p < 0.001) and the profiles of associa-
tions with cognitive deficits in primary analyses
were rather similar.
As expected, patients with better education per-
formed better in most domains except perceptual/
motor and abstraction/execution. One plausible
explanation was that levels of academic achieve-
ment simply reflected differences in premorbid in-
tellectual ability, hence the differences in cognitive
S.K. Liu, et al
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performances. However, it is complicated by the
fact that schizophrenia often develops insidiously
during critical periods of academic achievement
and that some attenuation is expected and the de-
gree of decrement cannot be exactly determined.44
In the current study, when the 22 (12.5%) sub-
jects who developed schizophrenia before com-
pleting their highest education were excluded, the
results of analysis were similar to those obtained
from the whole sample, indicating that the effects
of possible underestimation of baseline intellec-
tual ability by their educational achievement did
not significantly influence the results. In addi-
tion, the association between verbal IQ, which is
considered to be relatively well preserved in schiz-
ophrenia and approximates premorbid intellec-
tual ability,4 and education was modest (r = 0.55).
Education thus might have independent contri-
butions to cognitive performances other than gen-
eral intellectual ability. It might be hypothesized
that performances in tasks with at least some com-
ponents that are well learned before the onset of
disease are associated with education, such as ver-
bal ability and verbal memory, whilst those involv-
ing mainly visual-spatial ability and perception are
not. The unexpected finding of the negative con-
tribution of education to abstraction/execution
remains to be further explored.
The selective versus generalized issue might not
be of mere academic interest. Although the rela-
tionships between cognitive domain perform-
ances and subsequent psychosocial functioning
in the current sample are yet to be reported, as
types and severity of individual cognitive domain
deficits were associated with unique functional
outcome dimensions, they were important targets
of clinical assessments and treatment.45 Generally,
cognitive deficits did predict subsequent social
functioning, independent daily living and disabil-
ity level,46–48 and measures of cognitive function-
ing accounted for more variance in functional
capacity than did psychiatric ratings of symp-
toms.47 More specifically, verbal memory was asso-
ciated with all types of functional outcome;49
vigilance was related to social problem solving
and skill acquisition;50 and executive function
predicted community functioning but not social
problem solving.49 Since the current sample
tshowed overt deficits in all these domains, i
would be possible to examine whether they are in-
deed associated with different aspects of social and
tcommunity functions and predicted subsequen
functionality.
In conclusion, this study has provided informa-
tion on the severity and profile of neurocognitive
deficits in schizophrenic patients. Heterogeneity in
neurocognitive capacity was clearly demonstrated
and several potential contributing factors were
found. Subjects with different durations of illness
manifested specific patterns of deficits, and
memory-related functions seemed to deteriorate
with the passage of time, implying different trajec-
rtories taken by individual domains. The furthe
development of neurocognitive deficits awaits
confirmation from the results of longitudinal
follow-up studies.
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